Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest Drug-eluting stent Stories

2013-05-20 04:20:50

Results of Randomized JACK-EPC Trial Published in Minerva Cardioangiologica HONG KONG, May 20, 2013 /PRNewswire/ -- OrbusNeich today announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months. Data from JACK-EPC, an investigator-initiated randomized study, were published in the June issue of Minerva...

2013-05-17 04:20:42

NATICK, Mass., May 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint results for several trials will be presented, including the NG PROMUS trial, which evaluated our Promus PREMIER((TM)) Stent...

2013-05-16 20:22:40

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- -Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard(TM) Embolic Protection Stent- - Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a...

2013-05-16 08:27:27

Interventional Cardiology Pioneer Aims to Offer Improved Detection of Cardiovascular Disease SINGAPORE, May 16, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced on May 13, 2013 that it has entered into an agreement to acquire substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment...

2013-05-13 08:29:14

Results Will Be Presented During Symposium "Clinical Value of Anti-Restenosis and Pro-Healing COMBO Stent" and Oral Scientific Sessions HONG KONG, May 13, 2013 /PRNewswire/ -- OrbusNeich today announced that clinical results for the COMBO Dual Therapy Stent will be featured during EuroPCR 2013. Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, will present results from REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered...

2013-05-08 08:31:11

- Revenue increased 33% over prior year - BOSTON and TEL AVIV, Israel, May 8, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced financial results for the three month period ended March 31, 2013, the third quarter of its 2013 fiscal year. Revenue for the period increased by 33% over the March 31, 2012 quarter, reflecting the impact of several new marketing initiatives leveraging positive...

2013-05-02 08:37:52

Expanding Reimbursement Coverage to Drive Adoption of High-End Devices in the Long Term, According to Millennium Research Group TORONTO, May 2, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, favorable demographics and growing economies are the main factors spurring rising revenues in the Latin American interventional cardiology (IC) device market. Economic growth is contributing to increased...

2013-05-01 08:31:48

First heart pacemaker able to recruit stem cells to damaged heart tissue - THE MYOSTIM PACER - will be introduced LOS ANGELES, May 1, 2013 /PRNewswire/ -- Heart Rhythm 2013 will be held in Denver, Colorado May 8th to 11th - http://www.hrsonline.org/. Leonhardt Ventures and MyoStim Pacers are co-sponsoring @ 3pm on May 9(th) at their exhibit booth No. 657 a showcase of technologies that address heart and cardiovascular disease. Companies to be showcased include: MyoStim Pacers -...

2013-04-23 10:10:40

Researchers at the Stanford University School of Medicine have developed a method of predicting which patients with heart disease would benefit more from surgery and which would benefit more from angioplasty. Drawing on Medicare records of more than 100,000 patients with heart disease, the team demonstrated that the effectiveness of coronary bypass surgery varied widely based on each individual's characteristics. The data enabled them to predict which type of intervention – coronary...

2013-04-23 08:34:32

BOSTON and TEL-AVIV, Israel, April 23, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) Embolic Protection Stent (EPS), announced today that on April 19, 2013, the Company received an approval with conditions for its Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA). An approval with conditions indicates that the FDA concurs with the overall trial design and while...